Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

KITTEE TRC20 Token Ad

ANTX Quote Trading Chart AN2 Therapeutics Inc.


home / stock / antx / antx quote

$ Last:

-1.27% Change Percent:

$57.76 Open:

$56.86 Previous Close:

$58.14 High:

$56.86 Low:

315,708 Volume:

12/31/1969 07:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

ANTX Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2018-04-3057.7656.8658.1456.86315,708
2018-04-2756.9257.5957.8656.924,322,357
2018-04-2658.2757.2259.1057.004,430,352
2018-04-2555.0057.6157.7153.86011,725,049
2018-04-2454.8554.3154.9953.953,790,173
2018-04-2354.5054.565455.06954.43303,300
2018-04-2055.0054.5155.3154.3318,693
2018-04-1955.5454.935455.6754.745410,772
2018-04-1855.4055.6555.7755.3298554,234
2018-04-1754.6455.3655.819954.643,705,905
2018-04-1653.7854.3454.5853.77496,156
2018-04-1353.6153.5053.8653.46370,962
2018-04-1253.6053.1953.7853.122,404,746
2018-04-1154.1053.7554.1053.744,488
2018-04-1054.8354.8254.9154.7017,504
2018-04-0955.3754.3755.3754.31121,751
2018-04-0655.8154.9256.0954.4164,619
2018-04-0555.9656.3656.4455.6795127,237
2018-04-0455.3055.8555.8554.8522,219
Stock Information

AN2 Therapeutics Inc. Company Name:

ANTX Stock Symbol:

NYSE Market:

MENU
ANTX ANTX Quote ANTX Short ANTX News ANTX Articles ANTX Message Board
Get ANTX Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

KITTEE TRC20 Token Ad
RECENT ANTX NEWS
  • ANTX - AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

    Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volun...

  • ANTX - AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

    AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approv...

  • ANTX - AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

    On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Beg...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Telegram

Join us on Telegram

Join the Trending Stocks News on Telegram to get immediate news notifications!

Telegram


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2022 Market Wire News